Companies › Fujian Haixi Pharmaceuticals
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Ophthalmology; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HX9428 | – | Phase 1 | Wet Age-related Macular Degeneration (AMD) | Jul 2028 |
| C019199 | – | Phase 1 | Solid Tumor | – |
| Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 1 | Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06220318 | C019199 | Phase 1 | Solid Tumor | Oncology | Aug 2026 |
| NCT06220318 | Sintilimab | Phase 1 | Solid Tumor | Oncology | Aug 2026 |
| NCT07185841 | HX9428 | Phase 1 | Wet Age-related Macular Degeneration (AMD) | Ophthalmology | Jul 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.